Healthcare and Life Science
Why clinical safety should start before digital health products go live
Digital health innovation often moves quickly, but clinical safety must move with it from the beginning. For healthcare technology, safety is not simply a final compliance step; it should shape product design, user journeys, risk controls, implementation and ongoing monitoring.Many prom...
Sapphire Digital Health Advisory joins Cambridge Network
Sapphire Digital Health Advisory Ltd is pleased to join Cambridge Network as part of our commitment to collaboration, innovation and responsible digital health transformation.We are a UK-based clinical safety and digital health advisory company supporting health-tech, AI, occupational h...
Qureight to support Mediar Therapeutics’ Phase 2 trial of MTX-474 in diffuse cutaneous Systemic Sclerosis
Qureight’s AI-powered quantitative imaging analytics platform and services to analyse HRCT images to evaluate changes in compartment-specific lung biomarkersThe focus of these efforts will be on the quantitative assessment of change from baseline in lung fibrosisQureight’s imaging model...
Acteon launches AI training informed by behavioural science and AI best practice
Behaviour change consultancy Acteon has released free TikTok style training helping employees use AI safely, effectively and confidently. Free to download now. ...
Beyond the CV: How psychometric tools turn hiring from guesswork into strategy
A bad hire in a 15-person scale-up costs more than money. It costs momentum. By the time the role-fit problem is obvious, the person has been onboarded, given accounts, trusted with clients—and unpicking that takes months. SHRM puts the financial cost of a bad hire at around a third of ...
Reduce sickness absence, retain staff and increase productivity in your business
As it is Mental Health Awareness Week, it’s a perfect opportunity for me to reintroduce myself. ...
Enterprise Therapeutics achieves primary efficacy outcome in Phase 2 clinical trial for cystic fibrosis with novel inhaled ENaC blocker ETD001
First investigational inhaled ENaC blocker to deliver clinically relevant and statistically significant change in lung function compared to placebo Inhaled therapeutic designed to treat the 10% of people with cystic fibrosis with the highest unmet medical need ETD001 overall safe and we...
Cambridge NeuroWorks named “Tech for Good” winner for advancing breakthrough neurotechnology
Cambridge NeuroWorks has been named winner of the “Tech for Good” Award at the Cambridge Independent Science & Technology Awards 2026, recognising its rapid progress in accelerating breakthrough neurotechnologies with the potential to transform millions of lives. ...
Cambridge University Hospitals announces Nicola Ayton as Chief Executive
Cambridge University Hospitals NHS Foundation Trust (CUH) has appointed Nicola Ayton as Chief Executive, following a competitive recruitment process. She had been serving as interim Chief Executive since 1 January 2026. ...
Alfa Corporate Finance advises on the sale of Cambridge based Blue Scientific to Aptco Group
Alfa Corporate Finance has advised on the sale of BlueScientific to Aptco Group, supporting the shareholders from initial strategic review through to buyer selection, negotiation and completion. The transaction enables BlueScientific to join a broader pan-European platform while retaini...